GlassScriptPhysician profile
Mei Tang
NPI 1457495483
$3,325.26
in general payments reported to CMS, 2019-2025
35 companies · $1,381 in 2025
The $1,381 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $133 · 2022: $182 · 2023: $601 · 2024: $722 · 2025: $1,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,689 · Travel and Lodging: $14.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,689.28 |
| Travel and Lodging | $14.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $535.25 | 2019-2025 | Calquence, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $237.33 | 2019-2025 | Opdivo, Opdualag |
| Abbvie INC. | $186.66 | 2023-2025 | Venclexta |
| Janssen Biotech, INC. | $177.65 | 2019-2025 | Rybrevant, Erleada, Tecvayli |
| Daiichi Sankyo INC. | $174.70 | 2024-2025 | Enhertu |
| Genentech USA, INC. | $169.16 | 2023-2025 | Phesgo, Tecentriq, Polivy |
| Eisai INC. | $168.72 | 2020-2025 | |
| Grifols Shared Services North America, INC. | $145.62 | 2025 | Gamunex-C |
| Celgene Corporation | $127.59 | 2024-2025 | Reblozyl |
| Exelixis INC. | $123.35 | 2019-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $122.55 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Novartis Pharmaceuticals Corporation | $118.87 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $112.71 | 2023-2025 | Libtayo |
| Gilead Sciences, INC. | $101.15 | 2023-2024 | Trodelvy |
| Lilly USA, LLC | $92.60 | 2023-2025 | Jaypirca, Retevmo, Verzenio |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $92.49 | 2024-2025 | Jemperli, Zejula |
| Astellas Pharma US INC | $75.89 | 2019-2025 | Vyloy |
| Incyte Corporation | $72.86 | 2023-2025 | Monjuvi, Zynyz, Jakafi |
| Beigene USA, INC. | $50.00 | 2022 | |
| Foundation Medicine, INC. | $47.67 | 2019-2020 | |
| Caris Mpi, INC. | $41.51 | 2025 | Mi Cancer Seek |
| Pharmacyclics LLC, An Abbvie Company | $36.42 | 2020 | |
| Pfizer INC. | $34.30 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $28.98 | 2025 | |
| Mirati Therapeutics, INC. | $28.97 | 2023 | Krazati |
| Geron Corporation | $28.93 | 2025 | Rytelo |
| Genzyme Corporation | $27.56 | 2024 | |
| Kite Pharma, INC. | $26.97 | 2025 | Yescarta |
| Alexion Pharmaceuticals, INC. | $24.93 | 2024 | Ultomiris |
| Morphosys, US INC. | $24.79 | 2023 | Monjuvi |
| Taiho Oncology, INC. | $22.68 | 2024 | |
| Agios Pharmaceuticals, INC. | $17.79 | 2020 | |
| Emd Serono, INC. | $16.90 | 2019 | |
| Puma Biotechnology, INC. | $16.56 | 2025 | |
| Adc Therapeutics America, INC. | $15.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mei Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.